<DOC>
	<DOCNO>NCT01770223</DOCNO>
	<brief_summary>This study do find participant insulin resistance hepatitis C virus genotype 1 ( HCV GT1 ) infection fail dual therapy peginterferon alfa ( PegIFN ) + ribavirin ( RBV ) benefit addition boceprevir PegIFN + RBV ( triple therapy ) .</brief_summary>
	<brief_title>A Study Viral Response Triple Therapy Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy ( MK-3034-113 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Inclusion criterion : Quantifiable serum hepatitis C virusribonucleic acid ( HCVRNA ) Hepatitis C virus genotype 1 Homeostasis Model Assessment Insulin Resistance ( HOMA IR ) &gt; 2.5 two determination make 4 week apart ( first HOMA evaluation able make 3 week screen visit ) Previous failure achieve SVR PegIFN plus ribavirin give minimum 12 week without dose reduction 80 % adequate dos two drug No response , partial response , relapse previous therapy Compensated liver disease without histologic noninvasive evidence liver cirrhosis If heterosexually active , female participant childbearing potential nonvasectomized male participant female partner childbearing potential must agree use 2 effective contraceptive 6 month therapy end ( 7 month male subject ) Exclusion criterion : Coinfection HCV genotypes HCVGT1 Evidence decompensated liver disease History ascites , hepatic encephalopathy bleeding varix severe portal hypertension History sign symptoms evidence hepatocellular carcinoma ( HCC ) History organ transplant Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Severe psychiatric disease Inadequately control thyroid function Other important comorbidities ( cardiovascular disease , Type 1 diabetes inadequately control type 2 diabetes , malignancy , etc ) Substances abuse Alcohol intake &gt; 20 grams/day female &gt; 30 grams/day male History severe adverse event previous treatment PegIFN plus ribavirin include discontinuation therapy severe anemia hematologic toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>